HARBIN, China, March 30 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company has been awarded the prestigious High-Technology Enterprise certificate ("Certificate") by the government of Heilongjiang Province.
The Certificate was issued in accordance with the new 2008 "High-tech enterprise management standard" of the National Torch Plan, a program established in 1988 by China's Ministry of Science and Technology to encourage innovation and promote the development of China's high-tech industry. As a Certificate recipient, Renhuang will have access to a series of national and local government support programs, including favorable tax treatment, intellectual property protection, and technical support from the central and local government.
"Renhuang is honored to once again receive the Certificate, which has helped to enhance our internal R&D efforts," said Mr. Shaoming Li, the Chairman and CEO of Renhuang. "We appreciate the provincial government's recognition of the Company's scientific approach to new drug development, technological innovations and strong commitment to advancing medical research. Renhuang will continue to focus on leveraging our expertise and unique technologies to drive long-term, sustainable growth."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its financial guidance, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
CONTACT: Ms. Portia Tan, IR Contact of Renhuang Pharmaceuticals, Inc.,
+86-451-5392-5461, firstname.lastname@example.org; or Ms. Lei Huang, Account Manager,
+1-646- 833-3417 (New York), email@example.com, or Crocker Coulson,
President, +1- 646-213-1915 (New York), firstname.lastname@example.org, both of
CCG Investor Relations